

Matthias Eder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4842065/publications.pdf>

Version: 2024-02-01

46
papers

6,849
citations

159525

30
h-index

223716

46
g-index

48
all docs

48
docs citations

48
times ranked

4766
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. <i>Pharmaceuticals</i> , 2022, 15, 267.	1.7	1
2	The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2057-2058.	3.3	23
3	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. <i>Cancer Research</i> , 2021, 81, 2234-2245.	0.4	11
4	Library and post-translational modifications of peptide-based display systems. <i>Biotechnology Advances</i> , 2021, 47, 107699.	6.0	11
5	Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1461-1467.	2.8	9
6	[⁶⁸ Ga]Ga-PSMA-11: The First FDA-Approved ⁶⁸ Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2021, 14, 713.	1.7	55
7	PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. <i>Cancers</i> , 2021, 13, 3967.	1.7	20
8	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 70-79.	2.8	23
9	Development of PSMA-1007-Related Series of ¹⁸ F-Labeled Glu-Ureido-Type PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10897-10907.	2.9	18
10	[¹⁷⁷ Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. <i>Pharmaceuticals</i> , 2019, 12, 18.	1.7	41
11	Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 483-494.	0.5	1
12	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. <i>Cancer Research</i> , 2019, 79, 841-852.	0.4	33
13	Monomeric and Dimeric ⁶⁸ Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPs). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2062-2074.	2.9	27
14	PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 639-645.	2.8	89
15	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 8, 8-16.	1.2	8
16	Diagnostic performance of ⁶⁸ Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
17	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in ⁶⁸ Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 776-787.	3.3	124
18	Improving the Imaging Contrast of ⁶⁸ Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. <i>Bioconjugate Chemistry</i> , 2017, 28, 2485-2492.	1.8	40

#	ARTICLE	IF	CITATIONS
19	Preclinical Evaluation of ¹⁸ F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 425-431.	2.8	186
20	Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer. , 2017, , 51-58.		1
21	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <i>Theranostics</i> , 2016, 6, 1085-1095.	4.6	60
22	⁶⁸ Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e473-e479.	0.7	86
23	Radiation dosimetry of ⁶⁸ Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1611-1620.	3.3	143
24	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176.	2.8	475
25	Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1761-1775.	2.9	150
26	New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 9-15.	3.2	155
27	Comparison of hybrid ⁶⁸ Ga-PSMA PET/MRI and ⁶⁸ Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 70-83.	3.3	148
28	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 293-298.	2.8	100
29	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920.	2.8	451
30	[¹⁷⁷ Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 987-988.	3.3	155
31	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	2.8	332
32	The diagnostic value of PET/CT imaging with the ⁶⁸ Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209.	3.3	866
33	Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. <i>Prostate</i> , 2014, 74, 659-668.	1.2	93
34	Novel Preclinical and Radiopharmaceutical Aspects of [⁶⁸ Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2014, 7, 779-796.	1.7	323
35	Comparison of PET imaging with a ⁶⁸ Ga-labelled PSMA ligand and ¹⁸ F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 11-20.	3.3	817
36	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. <i>Clinical and Translational Imaging</i> , 2014, 2, 33-41.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH) ³ -Conjugates in Important Organs. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1327-1330.	2.8	24
38	PET/MRI with a ⁶⁸ Ga-PSMA ligand for the detection of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1629-1630.	3.3	72
39	PSMA as a target for radiolabelled small molecules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 819-823.	3.3	133
40	A dimerized urea-based inhibitor of the prostate-specific membrane antigen for ⁶⁸ Ga-PET imaging of prostate cancer. <i>EJNMMI Research</i> , 2012, 2, 23.	1.1	134
41	⁶⁸ Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. <i>Bioconjugate Chemistry</i> , 2012, 23, 688-697.	1.8	709
42	Zn(II)-bis(cyclen) Complexes and the Imaging of Apoptosis/Necrosis. <i>Bioconjugate Chemistry</i> , 2011, 22, 2611-2624.	1.8	26
43	⁶⁸ Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1397-1407.	3.3	50
44	ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [⁶⁸ Ga]PET imaging of VEGF receptors in angiogenic vasculature. <i>Nuclear Medicine and Biology</i> , 2010, 37, 405-412.	0.3	56
45	Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. <i>Nuclear Medicine and Biology</i> , 2010, 37, 885-891.	0.3	43
46	Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for ⁶⁸ Ga-labeled small recombinant antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1878-1886.	3.3	93